Hyperprogression as a distinct outcome after immunotherapy.

Area of Science:

• Oncology
• Immunology
• Cancer Therapeutics

Background:

• Immunotherapy offers new hope for cancer treatment by harnessing the immune system.
• However, a subset of patients (4-29%) experiences accelerated tumor progression, termed hyperprogression.
• Current RECIST criteria struggle to identify hyperprogression early, necessitating new assessment methods.

Purpose of the Study:

• To provide an updated overview of hyperprogressive disease (HPD) following immunotherapy.
• To discuss epidemiological data, clinical predictors, and potential biomarkers for HPD.
• To explore the molecular mechanisms underlying HPD.

Main Methods:

• Review of existing literature on immunotherapy and hyperprogression.
• Analysis of proposed parameters like Tumor Growth Rate (TGR) and Tumor Growth Kinetics (TGK).
• Examination of clinical and molecular factors associated with HPD.

Main Results:

• Hyperprogression is defined as RECIST progression with doubled growth pace post-treatment compared to pre-treatment.
• Factors associated with HPD include older age, high metastatic load, and prior irradiation.
• Biomarkers like MDM2 amplification and EGFR aberrations require validation; tumor mutation burden and circulating DNA are also potential indicators.

Conclusions:

• Hyperprogression presents a significant challenge in immunotherapy, distinct from pseudoprogression, and is linked to worse survival.
• Accurate identification of HPD risk is critical for optimizing cancer immunotherapy strategies.
• Further research into validated biomarkers and molecular drivers is essential for managing HPD.